Abstract
The rate of RNASEL 471delAAAG mutation was previously reported to be less than 7% in Ashkenazi prostate cancer patients. It seems plausible that the same mutation may also be involved in breast/ovarian cancer predisposition in Jewish individuals. To evaluate the role of this mutation in cancer predisposition, a total of 1011 individuals including 294 Jewish men with prostate cancer, 61 Ashkenazi women with ovarian cancer and 50 unaffected women, matched for age and ethnicity, were genotyped for sequence anomalies in a single RNASEL gene amplicon using DGGE and sequencing. Additionally, 209 Ashkenazi BRCA1/2 mutation carriers, 205 high-risk non-carriers matched for cancer type and age at diagnosis, and 192 healthy Ashkenazi women were screened, using DHPLC and restriction methods. The 471delAAAG mutation was detected in a single male with prostate cancer (1/294, 0.3%), in two ovarian cancer patients (2/141, 1.4%) and in one of 242 healthy controls (0.41%). An abnormal DHPLC profile identical to the one produced by the 471delAAAG mutation was noted in 23 additional women. The rate of this polymorphism was significantly elevated in high-risk non-carrier women (16/205; 7.8%) than in BRCA1/2 carriers (2/209; 1.0%) and controls (5/192; 2.6%) (χ = 11.670; P < 0.001). Sequence analysis disclosed a silent polymorphism in Valine at codon 118: c.353 C- > T.
The 471delAAAG mutation occurs rarely in Israeli prostate and breast/ovarian cancer patients. A silent polymorphism in the RNASEL gene occurs more␣prevalently in high-risk Ashkenazi breast/ovarian cancer patients without a BRCA1/2 mutation.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Damber L, Gronberg H, Damber JE (1998) Familial prostate cancer and possible associated malignancies: nation-wide register cohort study in Sweden. Int J Cancer 78:293–297
Carter BS, Beaty TH, Steinberg GD, Childs B, Walsh PC (1992) Mendelian inheritance of familial prostate cancer. Proc Natl Acad Sci USA 89:3367–3371
Carpten J, Nupponen N, Isaacs S, et al (2002) Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. Nat Genet 30:181–184
Smith JR, Freije D, Carpten JD, et al (1996) Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genomewide search. Science 274:1371–1374
Sood R, Bonner TI, Makalowska I, et al (2001) Cloning and characterization of 13 novel transcript and the human rgs8 gene from the 1q25 region encompassing the hereditary prostate cancer (hpc1) locus. Genomics 73:211–222
Silverman RH (2003) Implications for RNase L in prostate cancer biology. Biochemistry 42:1805–1812
Maier C, Haeusler J, Herkommer K, et al (2005) Mutation screening and association study of RNASEL as a prostate cancer susceptibility gene. Br J Cancer 92:1159–1164
Rokman A, Ikonen T, Seppala EH, et al (2002) Germline alterations of the RNASEL gene, a candidate HPC1 gene at 1q25, in patients and families with prostate cancer. Am J Hum Genet 70:1299–1304
Rennert H, Bercovich D, Hubert A, et al (2002) A novel founder mutation in the RNASEL gene, 471delAAAG, is associated with prostate cancer in Ashkenazi Jews. Am J Hum Genet 71:981–984
Kotar K, Hamel N, Thiffault I, Foulkes WD (2003) The RNASEL 471delAAAG allele and prostate cancer in Ashkenazi Jewish men. J Med Genet 40:e22
Israeli O, Gotlieb WH, Friedman E, et al (2004) Genomic analyses of primary and metastatic serous epithelial ovarian cancer. Cancer Genet Cytogenet 154:16–21
American Society of Clinical Oncology Policy Statement Update (2003) Genetic Testing for Cancer Susceptibility. JCO 21:2397–2406
Abeliovich D, Kaduri L, Lerer I, et al (1997) The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. Am J Hum Genet 60:505–514
Rohlfs EM, Learning WG, Friedman KJ, et al (1997) Direct detection of mutations in the breast and ovarian cancer susceptibility gene BRCA1 by PCR-mediated site-directed mutagenesis. Clin Chem 43:24–29
Casey G, Neville PJ, Plummer SJ, et al (2002) RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases. Nat Genet 32:581–583
Bruchim Bar-Sade R, Kruglikova A, Modan B, et al (1998) The 185delAG BRCA1 mutation originated before the dispersion of Jews in the Diaspora and is not limited to Ashkenazim. Hum Mol Genet 7:801–805
Patael Y, Figer A, Gershoni-Baruch R, et al (1999) Common origin of the I1307K APC polymorphism in Ashkenazi and non-Ashkenazi Jews. Eur J Hum Genet 7:555–559
Wang L, McDonnell SK, Elkins DA, et al (2002) Analysis of the RNASEL gene in familial and sporadic prostate cancer. Am J Hum Genet 71:116–123
Nakazato H, Suzuki K, Matsui H, et al (2003) Role of genetic polymorphisms of the RNASEL gene on familial prostate cancer risk in a Japanese population. Br J Cancer 89:691–696
Wiklund F, Jonsson BA, Brookes AJ, et al (2004) Genetic analysis of the RNASEL gene in hereditary, familial, and sporadic prostate cancer. Clin Cancer Res 10:7150–7156
Sevinc A, Yannoukakos D, Konstantopoulou I, et al (2004) Lack of association between RNASEL Arg462Gln variant and the risk of breast cancer. Anticancer Res 24:1547–1549
Author information
Authors and Affiliations
Corresponding author
Additional information
Efrat Dagan and Yael Laitman have equally contributed to this manuscript.
Rights and permissions
About this article
Cite this article
Dagan, E., Laitman, Y., Levanon, N. et al. The 471delAAAG Mutation and C353T Polymorphism in the RNASEL Gene in Sporadic and Inherited Cancer in Israel. Familial Cancer 5, 389–395 (2006). https://doi.org/10.1007/s10689-006-0010-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10689-006-0010-z